Cipla’s partner Sandoz gets USFDA’s nod for generic drug

30 Jul 2015 Evaluate

Cipla’s partner Sandoz has received approval from United States Food and Drug Administration (USFDA) to launch a generic version of Pulmicort respules (budesonide).

Sandoz’s budesonide inhalation suspension product is indicated for maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Budesonide inhalation suspension is not indicated for the relief of acute bronchospasm.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes over 2000 products in 65 therapeutic categories with one quality standard globally.

Cipla Share Price

1347.65 -10.15 (-0.75%)
27-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1738.10
Dr. Reddys Lab 1287.20
Cipla 1347.65
Zydus Lifesciences 922.50
Lupin 2301.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×